156 related articles for article (PubMed ID: 34863065)
1. Novel structural-related analogs of PFI-3 (SRAPs) that target the BRG1 catalytic subunit of the SWI/SNF complex increase the activity of temozolomide in glioblastoma cells.
He Y; Yang C; Wang Y; Sacher JR; Sims MM; Pfeffer LM; Miller DD
Bioorg Med Chem; 2022 Jan; 53():116533. PubMed ID: 34863065
[TBL] [Abstract][Full Text] [Related]
2. Targeting the Bromodomain of BRG-1/BRM Subunit of the SWI/SNF Complex Increases the Anticancer Activity of Temozolomide in Glioblastoma.
Yang C; Wang Y; Sims MM; He Y; Miller DD; Pfeffer LM
Pharmaceuticals (Basel); 2021 Sep; 14(9):. PubMed ID: 34577604
[TBL] [Abstract][Full Text] [Related]
3. Next-generation bromodomain inhibitors of the SWI/SNF complex enhance DNA damage and cell death in glioblastoma.
Yang C; He Y; Wang Y; McKinnon PJ; Shahani V; Miller DD; Pfeffer LM
J Cell Mol Med; 2023 Sep; 27(18):2770-2781. PubMed ID: 37593885
[TBL] [Abstract][Full Text] [Related]
4. The SMARCA2/4 ATPase Domain Surpasses the Bromodomain as a Drug Target in SWI/SNF-Mutant Cancers: Insights from cDNA Rescue and PFI-3 Inhibitor Studies.
Vangamudi B; Paul TA; Shah PK; Kost-Alimova M; Nottebaum L; Shi X; Zhan Y; Leo E; Mahadeshwar HS; Protopopov A; Futreal A; Tieu TN; Peoples M; Heffernan TP; Marszalek JR; Toniatti C; Petrocchi A; Verhelle D; Owen DR; Draetta G; Jones P; Palmer WS; Sharma S; Andersen JN
Cancer Res; 2015 Sep; 75(18):3865-3878. PubMed ID: 26139243
[TBL] [Abstract][Full Text] [Related]
5. Brahma-Related Gene-1 (BRG1) promotes the malignant phenotype of glioblastoma cells.
Wang Y; Yang CH; Schultz AP; Sims MM; Miller DD; Pfeffer LM
J Cell Mol Med; 2021 Mar; 25(6):2956-2966. PubMed ID: 33528916
[TBL] [Abstract][Full Text] [Related]
6. IKBKE enhances TMZ-chemoresistance through upregulation of MGMT expression in glioblastoma.
Guo G; Sun Y; Hong R; Xiong J; Lu Y; Liu Y; Lu J; Zhang Z; Guo C; Nan Y; Huang Q
Clin Transl Oncol; 2020 Aug; 22(8):1252-1262. PubMed ID: 31865606
[TBL] [Abstract][Full Text] [Related]
7. Nuclear factor I A promotes temozolomide resistance in glioblastoma via activation of nuclear factor κB pathway.
Yu X; Wang M; Zuo J; Wahafu A; Mao P; Li R; Wu W; Xie W; Wang J
Life Sci; 2019 Nov; 236():116917. PubMed ID: 31614149
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of cyclin E1 overcomes temozolomide resistance in glioblastoma by Mcl-1 degradation.
Liang H; Chen Z; Sun L
Mol Carcinog; 2019 Aug; 58(8):1502-1511. PubMed ID: 31045274
[TBL] [Abstract][Full Text] [Related]
9. DNA-methylation-mediated activating of lncRNA SNHG12 promotes temozolomide resistance in glioblastoma.
Lu C; Wei Y; Wang X; Zhang Z; Yin J; Li W; Chen L; Lyu X; Shi Z; Yan W; You Y
Mol Cancer; 2020 Feb; 19(1):28. PubMed ID: 32039732
[TBL] [Abstract][Full Text] [Related]
10. Visible Light and Glutathione Dually Responsive Delivery of a Polymer-Conjugated Temozolomide Intermediate for Glioblastoma Chemotherapy.
Du K; Xia Q; Sun J; Feng F
ACS Appl Mater Interfaces; 2021 Dec; 13(47):55851-55861. PubMed ID: 34788006
[TBL] [Abstract][Full Text] [Related]
11. Involvement of Intracellular Cholesterol in Temozolomide-Induced Glioblastoma Cell Death.
Yamamoto Y; Sasaki N; Kumagai K; Takeuchi S; Toyooka T; Otani N; Wada K; Narita Y; Ichimura K; Namba H; Mori K; Tomiyama A
Neurol Med Chir (Tokyo); 2018 Jul; 58(7):296-302. PubMed ID: 29899179
[TBL] [Abstract][Full Text] [Related]
12. miR-126-3p sensitizes glioblastoma cells to temozolomide by inactivating Wnt/β-catenin signaling via targeting SOX2.
Luo W; Yan D; Song Z; Zhu X; Liu X; Li X; Zhao S
Life Sci; 2019 Jun; 226():98-106. PubMed ID: 30980849
[TBL] [Abstract][Full Text] [Related]
13. The Bromodomains of the mammalian SWI/SNF (mSWI/SNF) ATPases Brahma (BRM) and Brahma Related Gene 1 (BRG1) promote chromatin interaction and are critical for skeletal muscle differentiation.
Sharma T; Robinson DCL; Witwicka H; Dilworth FJ; Imbalzano AN
Nucleic Acids Res; 2021 Aug; 49(14):8060-8077. PubMed ID: 34289068
[TBL] [Abstract][Full Text] [Related]
14. Effect of O6-Substituted Guanine Analogs on O6-methylguanine DNA-methyltransferase Expression and Glioblastoma Cells Viability.
St-Coeur PD; Cormier M; LeBlanc VC; Morin PJ; Touaibia M
Med Chem; 2016; 13(1):28-39. PubMed ID: 27396904
[TBL] [Abstract][Full Text] [Related]
15. Micro-RNA29b enhances the sensitivity of glioblastoma multiforme cells to temozolomide by promoting autophagy.
Xu JX; Yang Y; Zhang X; Luan XP
Anat Rec (Hoboken); 2021 Feb; 304(2):342-352. PubMed ID: 32275350
[TBL] [Abstract][Full Text] [Related]
16. Modulating lncRNA SNHG15/CDK6/miR-627 circuit by palbociclib, overcomes temozolomide resistance and reduces M2-polarization of glioma associated microglia in glioblastoma multiforme.
Li Z; Zhang J; Zheng H; Li C; Xiong J; Wang W; Bao H; Jin H; Liang P
J Exp Clin Cancer Res; 2019 Aug; 38(1):380. PubMed ID: 31462285
[TBL] [Abstract][Full Text] [Related]
17. BET bromodomain proteins are required for glioblastoma cell proliferation.
Pastori C; Daniel M; Penas C; Volmar CH; Johnstone AL; Brothers SP; Graham RM; Allen B; Sarkaria JN; Komotar RJ; Wahlestedt C; Ayad NG
Epigenetics; 2014 Apr; 9(4):611-20. PubMed ID: 24496381
[TBL] [Abstract][Full Text] [Related]
18. Oncogenesis caused by loss of the SNF5 tumor suppressor is dependent on activity of BRG1, the ATPase of the SWI/SNF chromatin remodeling complex.
Wang X; Sansam CG; Thom CS; Metzger D; Evans JA; Nguyen PT; Roberts CW
Cancer Res; 2009 Oct; 69(20):8094-101. PubMed ID: 19789351
[TBL] [Abstract][Full Text] [Related]
19. The TNF receptor family member Fn14 is highly expressed in recurrent glioblastoma and in GBM patient-derived xenografts with acquired temozolomide resistance.
Hersh DS; Harder BG; Roos A; Peng S; Heath JE; Legesse T; Kim AJ; Woodworth GF; Tran NL; Winkles JA
Neuro Oncol; 2018 Sep; 20(10):1321-1330. PubMed ID: 29897522
[TBL] [Abstract][Full Text] [Related]
20. Encapsulation of Temozolomide in a Calixarene Nanocapsule Improves Its Stability and Enhances Its Therapeutic Efficacy against Glioblastoma.
Renziehausen A; Tsiailanis AD; Perryman R; Stylos EK; Chatzigiannis C; O'Neill K; Crook T; Tzakos AG; Syed N
Mol Cancer Ther; 2019 Sep; 18(9):1497-1505. PubMed ID: 31213505
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]